GlassScriptPhysician profile
Peter Weissman
NPI 1841274529
$99,284.53
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $18K · 2021: $1,525 · 2022: $91.87.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $64,475.23 | 2019-2022 | |
| Amgen INC. | $30,892.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $3,220.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $175.43 | 2019-2020 | |
| Abbott Laboratories | $89.44 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $65.24 | 2019 | |
| Merck Sharp & Dohme LLC | $62.05 | 2019-2020 | |
| Senseonics, Incorporated | $62.00 | 2020 | |
| Medtronic, INC. | $47.22 | 2022 | |
| Insulet Corporation | $36.29 | 2020 | |
| Roche Diabetes Care, INC. | $35.32 | 2019 | |
| Lilly USA, LLC | $24.93 | 2019-2022 | |
| Medtronic Minimed, INC. | $24.79 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.54 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.65 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.63 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$7,278.36 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Weissman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.